A review article by Prof. Stefan Broer, Ph.D., highlights opportunities and challenges in using amino acid transporters as drug targets. Amino Acid Transporters as Disease Modifiers and Drug Targets provides an overview of methods used to identify new inhibitors for amino acid transporters and outlines cell and organ function where these can be used to modulate, prevent or to treat diseases.
Eight years in the making, a discovery by neuroscientists in Montreal highlights the value of long-term, fundamental research and provides important information for future drug targets.
It's one of the most talked about injuries in sport today, concussion. Yet, there is no accepted way to image a concussion. University of Calgary scientist Jeff Dunn, Ph.D., hopes to change that. He and his team have developed a portable brain imaging system that uses light to detect and monitor damage in the brain from concussion.
A new, biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer's disease (AD)-related amyloid-β peptide (Aβ) under near-infrared (NIR) light irradiation is developed. The catalyst was able to oxygenate Aβ embedded under the skin of a living mouse, and diminished intact Aβ level in AD-model mouse brain. The new catalyst is potentially applicable for the treatment of peripheral amyloid diseases and AD.
In a paper published online March 5 in Nature Communications, University of Washington researchers unveiled an open-access browser to display, analyze and share neurological data collected through a type of magnetic resonance imaging study known as diffusion-weighted MRI.
Neuroscientists at the Sainsbury Wellcome Centre have identified a circuit in the primary visual cortex (V1) of the brain that integrates head- and visual-motion signals. The study, published today in Neuron, elucidates the mechanisms by which visual and vestibular inputs to the brain sum together to enable appropriate behavioural responses.
New research led by Plymouth University Peninsula Schools of Medicine and Dentistry shows how the drug QNZ-46 can help to lessen the effects of excess release of glutamate in the brain -- the main cause of brain injury in stroke. As stroke is the second leading cause of disability and early death in the UK, this study could offer hope to thousands of people at risk.
A new study reveals that preverbal infants are able to make rational deductions, showing surprise when an outcome does not occur as expected.
University of Houston researchers link autism spectrum disorders to defects in a nuclear receptor inside the brain. And just like that, this world-renowned team advances the understanding of autism.
Treatments for the anti-NMDA receptor encephalitis usually include steroids, intravenous immunoglobulin, plasma exchange, plasmapheresis, rituximab, cyclophosphamide and tumor resection. The researchers aimed to compare the efficacy of the treatments including intravenous immunoglobulin, plasma exchange, plasmapheresis, rituximab or cyclophosphamide for male anti-NMDA receptor encephalitis patients without tumor and to discuss potential biomarkers for this disease.